The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. or A drug used to treat certain types of pancreatic cancer. It is also used to treat gastrointestinal stromal tumors (GIST) in some patients and to treat advanced kidney cancer. It is being studied in the treatment of other types of cancer. Sunitinib malate stops cancer cells from dividing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Also called SU011248, SU11248, sunitinib, and Sutent.